03.jpg

INNOVATION

Pipeline

OnQuality Pharmaceuticals is pioneering the field of targeted supportive cancer therapies. Our lead compound is an oncodermatology hand and foot ointment called OQL011, which is being evaluated for the treatment of Hand-Foot Skin Reaction, currently enrolling in Phase 2 clinical trials. We also have several pre-clinical assets that will enter clinical trials in the near future.  Additionally, we have two promising assets that are in the early discovery stage targeting oncogastroenterology conditions.

Therapeutic indication

Discovery

IND

Phase I

Phase II

Phase III

OQL011

VEGFR Inhibitor-induced hand-foot skin reaction

OQL012

VEGFR Inhibitor-induced hand-foot skin reaction

OQL025
EGFR Inhibitor-induced skin rash
OQL036
Chemotherapy-induced hand-foot syndrome
OQL041
EGFR inhibitor-induced diarrhea
OQL051
Chemotherapy-induced diarrhea
OQL061
IO-induced diarrhea / colitis
OQL071
Chemotherapy-induced alopecia